The sharp year-end rally in stocks extended into the first weeks of the New Year. Investors are now reassessing the valuations of risk assets as the spread of COVID-19 mutations along with logistical issues in manufacturing/distributing vaccines threaten to delay the economic recovery. We are neutral on our allocation to equities and await more favourable market entry points.